Form 4: Aligos Therapeutics Director Peter Hirth Executes Option Exchange Program

Director Peter Hirth participated in Aligos Therapeutics' option exchange program, canceling an existing option and receiving a replacement option with a lower exercise price.

Summary

• Peter Hirth, a director of Aligos Therapeutics, participated in the company's option exchange program.
• On February 27, 2024, Hirth's option for 15,000 shares, granted on June 17, 2021, with an exercise price of $26.58, was canceled.
• On February 28, 2024, Hirth received a replacement option for 4,411 shares with an exercise price of $0.96 per share.
• The replacement option vests one year from the grant date, contingent on continued service with the issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It describes a routine transaction related to executive compensation. The option exchange program could be seen as a positive for aligning management incentives, but it's not a major event.

Positives

• The option exchange program may incentivize continued service by aligning director interests with shareholder value through a lower exercise price.

Industry Context

Option exchange programs are sometimes used by companies to re-incentivize employees or directors, particularly when the stock price has fallen significantly below the original option exercise price. This can help retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Option exchange programs are a relatively common practice in the biotech industry, especially for companies whose stock prices have declined.
• Similar programs have been implemented by companies like Novavax and Sorrento Therapeutics to retain key personnel and align incentives.

Stakeholder Impact

• Shareholders may view the option exchange program as a way to retain and incentivize key personnel.
• Employees, particularly Peter Hirth, benefit from the lower exercise price of the replacement option.

Key Dates